Beth Fand Incollingo

Sotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.

The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma.

Immunotherapy with avelumab improved survival when given as maintenance therapy in patients whose disease did not progress on platinum-based chemotherapy.

States that expanded Medicaid coverage saw a steeper decline in cancer mortality rate, compared to those that didn’t follow the passage of the Affordable Care Act (ACA) of 2010.